[1] Ryman J et al. Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data. NPJ Vaccines. 2022;7(1):140. DOI: 10.1038/s41541-022-00538-1.
[2] Goettler D et al. Increase in Streptococcus pneumoniae serotype 3 associated parapneumonic pleural effusion/empyema after the introduction of PCV13 in Germany. Vaccine. 2020;38(3):570-577. DOI: 10.1016/j.vaccine.2019.10.056.
[3] Silva-Costa C et al. Continued Vaccine Breakthrough Cases of Serotype 3 Complicated Pneumonia in Vaccinated Children, Portugal (2016-2019). Microbiol Spectr. 2022;10(4):e0107722. DOI: 10.1128/spectrum.01077-22.
[4] Van der Linden M und Itzek A. SARS-COV-2 PANDEMIC INDUCED CHANGES IN SEROYPE PREVALENCE AMONG CHILDREN WITH INVASIVE PNEUMOCOCCAL DISEASE (IPD) IN GERMANY. European Society for Paediatric Infectious Diseases (ESPID) 2023; 08. – 12. Mai 2023 in Lissabon und virtuell. ePoster.
[5] Micoli F et al. Strengths and weaknesses of pneumococcal conjugate vaccines. Glycoconj J. 2023 40(2):135-148. DOI: 10.1007/s10719-023-10100-3.
[6] Dagan R. Relationship between immune response to pneumococcal conjugate vaccines in infants and indirect protection after vaccine implementation. Expert Rev Vaccines. 2019;18(6):641-661. DOI: 10.1080/14760584.2019.1627207.
[7] World Health Organization (WHO). Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper – February 2019. Wkly Epidemiol. Rec. 2019;94(08):85-103.
[8] Pichichero M et al. Acute otitis media pneumococcal disease burden and nasopharyngeal colonization in children due to serotypes included and not included in current and new pneumococcal conjugate vaccines. Expert Rev Vaccines. 2023;22(1):118-138. DOI: 10.1080/14760584.2023.2162506.
[9] European Centre for Disease Prevention and Control (ECDC). Invasive pneumococcal disease – Annual Epidemiological Report for 2018. Stand: 2020. https://www.ecdc.europa.eu/en/publications-data/invasive-pneumococcal-disease-annual-epidemiological-report-2018 [eingesehen am 29.11.2023].
[10] Balsells E et al. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and metaanalysis. PLoS One.
[11] Martinon-Torres F et al. A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1). Vaccine. 2023;41(21):3387–3398.
[12] Fachinformation VAXNEUVANCE®, Stand November 2023.
[13] Robert Koch-Institut (RKI). Empfehlungen der Ständigen Impfkommission (STIKO) beim Robert Koch-Institut 2023. Epid Bull 2023;4:3-68.
[14] Gemeinsamer Bundesausschuss (G-BA). Richtlinie des Gemeinsamen Bundesausschusses über Schutzimpfungen nach § 20i Absatz 1 SGB V. Zuletzt geändert am 20.07.2023 und in Kraft getreten am 14.09.2023, Online verfügbar unter: https://www.g-ba.de/richtlinien/60/ [eingesehen am 29.11.2023].
